CytomX Initiates $250M Offering as Varseta-M Phase I Shows 32% Response
CytomX Therapeutics has launched a $250 million underwritten offering with a $37.5 million overallotment to fund its PROBODY platform. Its Varseta-M Phase I showed 32% response at 10 mg/kg and 20% at 8.6 mg/kg, and the company’s market cap is about $400 million.
1. Public Offering Launch
CytomX Therapeutics commenced an underwritten offering of up to $250 million in common shares and pre-funded warrants, plus a $37.5 million overallotment option. Proceeds are designated to advance its PROBODY platform and support pipeline programs including Varseta-M and CX-801.
2. Varseta-M Phase I Outcomes
In heavily pretreated metastatic colorectal cancer patients, Varseta-M delivered confirmed response rates of 32% at a 10 mg/kg dose and 20% at 8.6 mg/kg. The company plans mid-2026 discussions with regulators to define a potential registrational trial design.
3. Market Metrics and Valuation
At the time of the offering announcement, CytomX’s market capitalization stood at approximately $400 million, with intraday trading volumes surpassing 121 million shares and notable volatility. Oppenheimer continues to rate the stock as Outperform.